Hemopure to BPAC
Executive Summary
Biopure's oxygen therapeutic Hemopure (hemoglobin glutamer - 250 [bovine]) for out-of-hospital treatment of hemorrhagic shock due to traumatic injury will be the subject of a closed-door review by FDA's Blood Products advisory committee July 14, the company said. BPAC will also hear FDA's review of Nabi Biopharmaceuticals' Hepatitis B Immunoglobulin Intravenous for prevention of recurrent Hepatitis B Virus Disease after orthotopic liver transplantation July 13. Nabi-HB is already approved for intramuscular use (1"The Pink Sheet" March 29, 1999, In Brief)...